We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

42 hedge funds and large institutions have $119M invested in Strongbridge Biopharma plc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more call options, than puts

Call options by funds: $51K | Put options by funds: $29K

9.46% less ownership

Funds ownership: 65.66% → 56.2% (-9.5%)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

14% less funds holding

Funds holding: 49 → 42 (-7)

20% less capital invested

Capital invested by funds: $149M → $119M (-$29.9M)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
42
Holders Change
-7
Holders Change %
-14.29%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
14
Reduced
16
Closed
16
Calls
$51K
Puts
$29K
Net Calls
+$22K
Net Calls Change
-$6K

SBBP Hedge Fund Activity: Q4 2018 in Review

42 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2018, worth a combined $119M — down 20% from $149M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SBBP and 9 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.

The largest buyer was 683 Capital Management, adding an estimated $2.68M. The largest seller was Lyon Street Capital, exiting entirely with an estimated $13.9M sold.

  • 42 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2018, down from 49 in Q3 2018.
  • Funds reported $119M of Strongbridge Biopharma plc. stock for Q4 2018, down 20% quarter-over-quarter.
  • 9 funds opened new Strongbridge Biopharma plc. positions in Q4 2018 and 16 closed out, a net change of -7 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q4 2018 was 683 Capital Management, an estimated $2.68M added.
  • The largest Strongbridge Biopharma plc. seller in Q4 2018 was Lyon Street Capital, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2018.